Elmind Capital LP Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Elmind Capital LP acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,150,000 shares of the biotechnology company’s stock, valued at approximately $16,770,000. BioCryst Pharmaceuticals makes up approximately 4.9% of Elmind Capital LP’s portfolio, making the stock its 7th biggest holding. Elmind Capital LP owned about 1.02% of BioCryst Pharmaceuticals as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Larson Financial Group LLC increased its position in BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,267 shares in the last quarter. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $77,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares in the last quarter. Vestmark Advisory Solutions Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $8.95 on Thursday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $10.32. The company has a 50 day moving average of $8.92 and a 200-day moving average of $8.16. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of -5.03 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BCRX shares. Wedbush lowered their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Citizens Jmp raised their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Evercore started coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price target for the company. Finally, Needham & Company LLC lowered their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.